Why does everyone want to go to the Buyside?

I work in SS ER covering biotech. Currently I’m junior but lately have been thinking if I should move to the Buyside.

Everything I see on this forum is HF guys hardly breaking 1 M on a good year. Why can’t I just coast in ER and make $1.5-$2.5 million? If I’m really good then make $4-$8 million a year.

Call me crazy but a HF doesn’t seems crazy lucrative when I can already make million on the SS.

26 Comments
 

How about you go get a deep understanding of what it takes to become a Senior SS Analyst first and what their lifestyle is

  • managing relationships with 20+ company management (for biotech, maybe even more), buy-side clients, equity sales, media
  • doing 3-4 big marketing trips each year
  • hosting at least one big conference
  • taking client calls all day
  • writing quarterly earnings maintenance notes that no one reads and also thematic notes
  • initiating on all the IPOs if at a good deal flow bank so you have a shot at that $1mm+ comp for bringing the deals in
  • putting a big show to participate in the zero sum game that's called II voting?

Then re-assess do you really want to become a senior sell-side analyst?

 
Most Helpful

The highest paid SS senior analyst right now within biotech, which is also one of the highest comping sector within finance SS ER, is $8 mn for 5 years.

$1-$2 mn definitely possible for SS ER. $5-$8 mn is defnitely the outlier, but representative of the absolute top of the industry. You will always be beholden to trading your time for money.

$20 mn/yr to $1 bn/yr is never possible on sell-side. It is possible on buyside. Certainly a tail outcome, but that's one draw for buyside. If you manage a $1 bn fund or larger, and there are a number of those, then comp in that range is a reality if your performance is decent. If your fund is successful enough, you can hire enough people to where you may oversee the processes and make the final decision, but most day to day operations are pushed to other people. You have equity in a business that can continue to generate profits as you enjoy life.

The other draw is that it's a very different job. In SS ER, you have two masters, buyside investors and corporates. Obviously, in many cases, these interests misalign. Part of your job as SS ER is walk the tightrope that is not having either side get too upset by what you are publicly (and often irrevocably) saying. At a HF, you have one job: make money for your clients. In many ways, it's a much simpler and straightforward job, but obviously execution is the differentiator.

 

He’s a creepy weirdo and most biotech investors dislike him. 

 

lmao these are starting to sound like professional sports contracts. My man getting better contracts than NFL Top tier Running Backs! And don't get me started on the longevity :P. 

For real though, what is it with biotech that makes SS analysts in that sector top out at multiples above the other sectors? There must be an industry specific P&L driver but I just don't know what it is 

 

Client service sounds like hell, no time for deep work cause always traveling / publishing notes

You’re basically doing same buyside stuff as the buyside, but removing the fun aspects and replacing it with alotta BS. I get it if you’re like ‘the guy’ in a sector, the guru at an independent shop and if u like that type of work. Personally having to get notes out on a deadline and answer to client calls and requests, with my actual comp/rev-generation potentially somewhat arbitrary to my research quality sounds more stressful to me and the stress of putting risk on in a portfolio 

 

Maybe it’s just me, but what is the likelihood of you becoming the “top” research analyst for your sector and consistently getting paid $2M+. I’d say you’re more likely to get Partner at a MF or big HF. You typically don’t get there until 45+ at least so that seems like a hell of a harder job / bet you’re making on your career than being an average buysider.

 

Molestiae sint saepe dolorem ut. Quia blanditiis itaque eos. Vitae est accusamus unde culpa qui dignissimos. Id dolor sequi vitae. Suscipit facilis nulla consequatur consequatur natus quia beatae. Sint voluptatem vel eos vel id voluptatibus modi et.

Ullam porro voluptatem reprehenderit maxime explicabo quia. Omnis tempore aut sunt enim. Atque consequuntur laudantium nisi distinctio ab voluptate. Commodi ab aut molestiae adipisci et.

Tenetur eos eius sapiente in in. At enim voluptatem dignissimos. Perspiciatis sit et et doloribus.

Career Advancement Opportunities

June 2026 Hedge Fund

  • Point72 99.0%
  • D.E. Shaw 98.1%
  • Citadel Investment Group 97.1%
  • AQR Capital Management 96.1%
  • Magnetar Capital 95.1%

Overall Employee Satisfaction

June 2026 Hedge Fund

  • Magnetar Capital 99.0%
  • D.E. Shaw 98.0%
  • Blackstone Group 97.0%
  • Citadel Investment Group 96.0%
  • Millennium Partners 95.0%

Professional Growth Opportunities

June 2026 Hedge Fund

  • AQR Capital Management 99.0%
  • Point72 98.1%
  • D.E. Shaw 97.1%
  • Citadel Investment Group 96.2%
  • Magnetar Capital 95.2%

Total Avg Compensation

June 2026 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (27) $464
  • Director/MD (12) $423
  • NA (9) $320
  • Engineer/Quant (86) $288
  • 3rd+ Year Associate (26) $284
  • Manager (4) $282
  • 2nd Year Associate (32) $253
  • 1st Year Associate (76) $192
  • Analysts (242) $181
  • Intern/Summer Associate (29) $145
  • Junior Trader (5) $102
  • Intern/Summer Analyst (282) $96
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”